Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT

Vamsi Mohan Meka, Baphiralyne Wankhar, Vijayanadh Ojili, Prem P. Batchala

Research output: Contribution to journalArticlepeer-review


18F-fluciclovine is a radiolabeled synthetic amino acid recently approved by the Food and Drug Administration for evaluating recurrent prostate cancer. Upregulated amino acid transporters in prostate cancer cells result in elevated radiotracer uptake in sites of tumor recurrence. However, 18F-fluciclovine is not specific for prostate cancer. Nonprostatic malignancies and benign conditions can also demonstrate uptake. This information combined with the knowledge about common patterns of prostate cancer recurrence helps guide appropriate management. We present an 87-year-old man with biochemical recurrence for prostate cancer but found to have a urinary bladder wall mass on 18F-fluciclovine PET/CT with moderate avidity. Biopsy revealed papillary urothelial carcinoma.

Original languageEnglish (US)
Pages (from-to)E438-E439
JournalClinical nuclear medicine
Issue number8
StatePublished - 2021


  • F-fluciclovine
  • PET/CT
  • papillary urothelial carcinoma
  • urinary bladder

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT'. Together they form a unique fingerprint.

Cite this